These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 31419574)

  • 1. Stopping Mesalamine Therapy in Patients With Crohn's Disease Starting Biologic Therapy Does Not Increase Risk of Adverse Outcomes.
    Ungaro RC; Limketkai BN; Jensen CB; Yzet C; Allin KH; Agrawal M; Ullman T; Burisch J; Jess T; Colombel JF
    Clin Gastroenterol Hepatol; 2020 May; 18(5):1152-1160.e1. PubMed ID: 31419574
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Stopping 5-aminosalicylates in patients with ulcerative colitis starting biologic therapy does not increase the risk of adverse clinical outcomes: analysis of two nationwide population-based cohorts.
    Ungaro RC; Limketkai BN; Jensen CB; Allin KH; Agrawal M; Ullman T; Colombel JF; Jess T
    Gut; 2019 Jun; 68(6):977-984. PubMed ID: 30420398
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Continuing or stopping 5-aminosalicylates in patients with inflammatory bowel disease on anti-TNF therapy: A nationwide population-based study.
    Seo J; Kim S; Hong SW; Hwang SW; Park SH; Yang DH; Byeon JS; Myung SJ; Yang SK; Kim YJ; Ye BD
    Aliment Pharmacol Ther; 2024 Aug; 60(3):389-400. PubMed ID: 38866064
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of thiopurine discontinuation at anti-tumour necrosis factor initiation in inflammatory bowel disease treatment: a nationwide Danish cohort study.
    Thomsen SB; Ungaro RC; Allin KH; Elmahdi R; Poulsen G; Andersson M; Colombel JF; Jess T
    Aliment Pharmacol Ther; 2022 May; 55(9):1128-1138. PubMed ID: 35080036
    [TBL] [Abstract][Full Text] [Related]  

  • 5. No Benefit of Continuing 5-Aminosalicylates in Patients with Crohn's Disease Treated with Anti-metabolite Therapy.
    Picetti D; Kim J; Zhu W; Sandborn WJ; Jairath V; Singh S
    Dig Dis Sci; 2022 Jul; 67(7):3115-3123. PubMed ID: 34797442
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Early Ileocecal Resection for Crohn's Disease Is Associated With Improved Long-term Outcomes Compared With Anti-Tumor Necrosis Factor Therapy: A Population-Based Cohort Study.
    Agrawal M; Ebert AC; Poulsen G; Ungaro RC; Faye AS; Jess T; Colombel JF; Allin KH
    Gastroenterology; 2023 Oct; 165(4):976-985.e3. PubMed ID: 37321356
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Upfront Combination Therapy, Compared With Monotherapy, for Patients Not Previously Treated With a Biologic Agent Associates With Reduced Risk of Inflammatory Bowel Disease-related Complications in a Population-based Cohort Study.
    Targownik LE; Benchimol EI; Bernstein CN; Singh H; Lix L; Tennakoon A; Leung S; Aviña A; Coward S; Jones J; Kaplan G; Murthy SK; Nguyen GC; Peña-Sánchez JN
    Clin Gastroenterol Hepatol; 2019 Aug; 17(9):1788-1798.e2. PubMed ID: 30448599
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of early anti-TNF use on clinical outcomes in Crohn's disease: a nationwide population-based study.
    Jung YS; Han M; Park S; Cheon JH
    Korean J Intern Med; 2020 Sep; 35(5):1104-1113. PubMed ID: 32306709
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Visceral adiposity and inflammatory bowel disease.
    Rowan CR; McManus J; Boland K; O'Toole A
    Int J Colorectal Dis; 2021 Nov; 36(11):2305-2319. PubMed ID: 34104989
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Aminosalicylates for induction of remission or response in Crohn's disease.
    Lim WC; Wang Y; MacDonald JK; Hanauer S
    Cochrane Database Syst Rev; 2016 Jul; 7(7):CD008870. PubMed ID: 27372735
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Colonoscopy-guided therapy for the prevention of post-operative recurrence of Crohn's disease.
    Candia R; Bravo-Soto GA; Monrroy H; Hernandez C; Nguyen GC
    Cochrane Database Syst Rev; 2020 Aug; 8(8):CD012328. PubMed ID: 32746500
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Stopping anti-tumour necrosis factor therapy in patients with perianal Crohn's disease.
    Mak JWY; Tang W; Yip TCF; Ran ZH; Wei SC; Ahuja V; Kumar S; Leung WK; Hilmi I; Limsrivilai J; Aniwan S; Lam BCY; Chan KH; Ng KM; Leung CM; Li MKK; Lo FH; Sze ASF; Tsang SWC; Hui AJ; Hartono JL; Ng SC
    Aliment Pharmacol Ther; 2019 Dec; 50(11-12):1195-1203. PubMed ID: 31638274
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative Effectiveness and Safety of Anti-Tumor Necrosis Factor Agents in Biologic-Naive Patients With Crohn's Disease.
    Singh S; Heien HC; Sangaralingham LR; Schilz SR; Kappelman MD; Shah ND; Loftus EV
    Clin Gastroenterol Hepatol; 2016 Aug; 14(8):1120-1129.e6. PubMed ID: 27058635
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Vedolizumab Is Associated With a Lower Risk of Serious Infections Than Anti-Tumor Necrosis Factor Agents in Older Adults.
    Kochar B; Pate V; Kappelman MD; Long MD; Ananthakrishnan AN; Chan AT; Sandler RS
    Clin Gastroenterol Hepatol; 2022 Jun; 20(6):1299-1305.e5. PubMed ID: 34481954
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of tumor necrosis factor-α inhibitors on drug-induced pancreatitis in inflammatory bowel disease.
    Stobaugh DJ; Deepak P
    Ann Pharmacother; 2014 Oct; 48(10):1282-7. PubMed ID: 24982311
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combined Biologic and Immunomodulatory Therapy is Superior to Monotherapy for Decreasing the Risk of Inflammatory Bowel Disease-Related Complications.
    Targownik LE; Benchimol EI; Bernstein CN; Singh H; Tennakoon A; Zubieta AA; Coward S; Jones J; Kaplan GG; Kuenzig ME; Murthy SK; Nguyen GC; Peña-Sánchez JN
    J Crohns Colitis; 2020 Oct; 14(10):1354-1363. PubMed ID: 32648579
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anxiety and Depression Leads to Anti-Tumor Necrosis Factor Discontinuation in Inflammatory Bowel Disease.
    Dolovich C; Bernstein CN; Singh H; Nugent Z; Tennakoon A; Shafer LA; Marrie RA; Sareen J; Targownik LE
    Clin Gastroenterol Hepatol; 2021 Jun; 19(6):1200-1208.e1. PubMed ID: 32668341
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of Concomitant Immunomodulator Therapy on Efficacy and Safety of Anti-Tumor Necrosis Factor Therapy for Crohn's Disease: A Meta-analysis of Placebo-controlled Trials.
    Jones JL; Kaplan GG; Peyrin-Biroulet L; Baidoo L; Devlin S; Melmed GY; Tanyingoh D; Raffals L; Irving P; Kozuch P; Sparrow M; Velayos F; Bressler B; Cheifetz A; Colombel JF; Siegel CA
    Clin Gastroenterol Hepatol; 2015 Dec; 13(13):2233-40.e1-2; quiz e177-8. PubMed ID: 26142167
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Indicators of suboptimal response to anti-tumor necrosis factor therapy in patients from China with inflammatory bowel disease: results from the EXPLORE study.
    Li J; Liu Z; Hu P; Wen Z; Cao Q; Zou X; Chen Y; Wang Y; Zhong J; Shen X; Demuth D; Fadeeva O; Xie L; Chen J; Qian J
    BMC Gastroenterol; 2022 Feb; 22(1):44. PubMed ID: 35120446
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reduced Imaging Radiation Exposure and Costs Associated with Anti-Tumor Necrosis Factor Therapy in Crohn's Disease.
    Patil SA; Flasar MH; Lin J; Lingohr-Smith M; Skup M; Wang S; Chao J; Cross RK
    Dig Dis Sci; 2019 Jan; 64(1):60-67. PubMed ID: 30311154
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.